HIV AIDS. Human immunodeficiency virus [HIV]
Conditions
Interventions
Intervention 1: control group : there are any interventions in this group. Intervention 2: The patients group who administrated above drugs for surviving their effect on latent virus reactivation.
A-
Treatment - Drugs
control group : there are any interventions in this group
The patients group who administrated above drugs for surviving their effect on latent virus reactivation.
A- sampling:
1- bloodletting 10 ml from patients.
2-after inclusion the samples the RNA vir
Sponsors
Resaerch Deputy tehran university of medical sciences
Eligibility
Sex/Gender
All
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: latent HIV-1 infected persons; confirm their sero positive infection by ELISA or WESTERN BLOT in last year; men, women age 4018 years old; plasma HIV-1 RNA 10 gr/dl, Plt count >105 /microlit, Creatinine clearance >50 gr/dl, Neu count >.75×109 cell/ml, Hepatic Trans aminase 80%; DNA proviral prior to study 10<x<1000 copy/ 1000000 PBMCs; signing the written informed consent by person. Exclusion criteria: sero positive person for HBV / HPV/ HCV/ EBV/ GBV/ CMV/ opportunistic infection andUntreatedfungal infectious for at least 2 months; pregnant and foster women; person who under treatment of immunological drugs; person who wasn’t surviving for any kind of cancer since 5 years ago; person who has hyperaesthesia to immune vaccine and who has hyperaesthesia to immune disease like Hashimoto's thyroiditisand SLE; abuser of alcohol and drug; person who took cytotoxic drug and systemic Corticosteroid 4 weeks before study at least; untreated hypertension; person who has coagulating disorders; person who has Pancreatitis , liver and kidney 's disorders; person who has intense myocardial disease and Coronary artery; person who has psychosis; person who has taken Asprin/ Warfarin/ Phenobarbital/ Maraviroc/ Tipranavir/ Phenytoin/ Carbamazepine daily; person who has signs of MAC 2 months prior study; person who has allergy to VPA and DSF.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in DNA viral load. Timepoint: 14 days , 16 weeks. Method of measurement: blood sample. | — |
Secondary
| Measure | Time frame |
|---|---|
| CD4 count. Timepoint: 17 Weeks. Method of measurement: blood sample. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMinoo Mohraz MD
Iranian research Center for HIV AIDS (IRCHA)
Outcome results
None listed